Literature DB >> 21685036

Classical-type invasive lobular carcinoma with HER2 overexpression: clinical, histologic, and hormone receptor characteristics.

Jing Yu1, David J Dabbs, Yongli Shuai, Leo A Niemeier, Rohit Bhargava.   

Abstract

The majority of invasive lobular carcinomas (ILCs) express estrogen receptor (ER) and progesterone receptor (PR) but lack ERBB2 (HER2) amplification. HER2 overexpression is traditionally considered to occur in the pleomorphic variant of ILCs. We describe 12 cases of classical-type ILCs with HER2 overexpression in a 3-year period. All tumors displayed the characteristic morphologic features of classical ILC with uniform cells and discohesive growth patterns. The lobular phenotype was confirmed by the absence of E-cadherin staining. Multiple variables regarding clinical, histologic, and hormone receptor characteristics of tumors were evaluated and compared with a set of HER2- classical ILCs. The study identified 2 main pathologic features associated with HER2 overexpression in classical type ILC: histiocytoid morphologic features and absence of PR expression. ER is still expressed in HER2+ classical ILCs, although the level of expression is significantly reduced compared with the HER2- cases. The implications of the findings are discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21685036     DOI: 10.1309/AJCP7URIW0QETTAT

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  13 in total

1.  Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials.

Authors:  José Pérez-Garcia; Javier Cortés; Otto Metzger Filho
Journal:  Oncologist       Date:  2018-12-21

Review 2.  Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications.

Authors:  Romualdo Barroso-Sousa; Otto Metzger-Filho
Journal:  Ther Adv Med Oncol       Date:  2016-04-25       Impact factor: 8.168

Review 3.  Applying the New Guidelines of HER2 Testing in Breast Cancer.

Authors:  Huina Zhang; Ioana Moisini; Rana M Ajabnoor; Bradley M Turner; David G Hicks
Journal:  Curr Oncol Rep       Date:  2020-04-29       Impact factor: 5.075

4.  Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients).

Authors:  Vahit Özmen
Journal:  J Breast Health       Date:  2014-04-01

Review 5.  Invasive lobular carcinoma: an understudied emergent subtype of breast cancer.

Authors:  Jason A Mouabbi; Amy Hassan; Bora Lim; Gabriel N Hortobagyi; Debasish Tripathy; Rachel M Layman
Journal:  Breast Cancer Res Treat       Date:  2022-03-26       Impact factor: 4.872

6.  Histiocytoid breast carcinoma: a case report showing immunohistochemical profiles.

Authors:  Peifeng Li; Jinfeng Zheng; Tingguo Zhang; Ruixue Cao; Xin Chen; Ming Geng
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

7.  Tumor characteristics and the clinical outcome of invasive lobular carcinoma compared to infiltrating ductal carcinoma in a Chinese population.

Authors:  A-Yong Cao; Liang Huang; Jiong Wu; Jin-Song Lu; Guang-Yu Liu; Zhen-Zhou Shen; Zhi-Ming Shao; Gen-Hong Di
Journal:  World J Surg Oncol       Date:  2012-07-17       Impact factor: 2.754

8.  Correlation of Prognostic Factors of Invasive Lobular Carcinoma with ADC Value of DWI and SUVMax of FDG-PET.

Authors:  Bo Bae Choi; Sung Hun Kim; Chang Suk Park; Na Young Jung
Journal:  Chonnam Med J       Date:  2017-05-25

9.  Human epidermal growth factor receptor 2 positive rates in invasive lobular breast carcinoma: The Singapore experience.

Authors:  Ga-Jing Kee; Ryan Ying-Cong Tan; Sultana Rehena; Joycelyn Jie-Xin Lee; Ma Wai-Wai Zaw; Wei-Xiang Lian; Joe Yeong; Su-Ming Tan; Swee-Ho Lim; Benita Kiat-Tee Tan; Yoon-Sim Yap; Rebecca Alexandra Dent; Fuh-Yong Wong; Guek-Eng Lee
Journal:  World J Clin Oncol       Date:  2020-05-24

10.  Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.

Authors:  Chitra Joseph; Olivia Macnamara; Madeleine Craze; Roslin Russell; Elena Provenzano; Christopher C Nolan; Maria Diez-Rodriguez; Sultan N Sonbul; Mohammed A Aleskandarany; Andrew R Green; Emad A Rakha; Ian O Ellis; Abhik Mukherjee
Journal:  Br J Cancer       Date:  2018-03-28       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.